Literature DB >> 27826151

Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Wasim S El Nekidy1, Maher M El-Masri2, Greg S Umstead3, Michelle Dehoorne-Smith4.   

Abstract

BACKGROUND: Methicillin-resistant Staphylococcus aureus is a leading cause of death in patients undergoing hemodialysis. However, controversy exists about the optimal dose of vancomycin that will yield the recommended pre-hemodialysis serum concentration of 15-20 mg/L.
OBJECTIVE: To develop a data-driven model to optimize the accuracy of maintenance dosing of vancomycin for patients undergoing hemodialysis.
METHODS: A prospective observational cohort study was performed with 164 observations obtained from a convenience sample of 63 patients undergoing hemodialysis. All vancomycin doses were given on the floor after completion of a hemodialysis session. Multivariate linear generalized estimating equation analysis was used to examine independent predictors of pre-hemodialysis serum vancomycin concentration.
RESULTS: Pre-hemodialysis serum vancomycin concentration was independently associated with maintenance dose (B = 0.658, p < 0.001), baseline pre-hemodialysis serum concentration of the drug (B = 0.492, p < 0.001), and interdialytic interval (B = -2.133, p < 0.001). According to the best of 4 models that were developed, the maintenance dose of vancomycin required to achieve a pre-hemodialysis serum concentration of 15-20 mg/L, if the baseline serum concentration of the drug was also 15-20 mg/L, was 5.9 mg/kg with interdialytic interval of 48 h and 7.1 mg/kg with interdialytic interval of 72 h. However, if the baseline pre-hemodialysis serum concentration was 10-14.99 mg/L, the required dose increased to 9.2 mg/kg with an interdialytic interval of 48 h and 10.0 mg/kg with an interdialytic interval of 72 h.
CONCLUSIONS: The maintenance dose of vancomycin varied according to baseline pre-hemodialysis serum concentration of the drug and interdialytic interval. The current practice of targeting a pre-hemodialysis concentration of 15-20 mg/L may be difficult to achieve for the majority of patients undergoing hemodialysis.

Entities:  

Keywords:  dosing; hemodialysis; vancomycin

Year:  2016        PMID: 27826151      PMCID: PMC5085318          DOI: 10.4212/cjhp.v69i5.1588

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  28 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Vancomycin dosing nomogram for haemodialysis patients.

Authors:  Cameron J Jeremiah; Carly Wills; Angela Bayly; Greg J Perry; Joshua S Davis; Steven Y Tong; Bart J Currie
Journal:  Nephrology (Carlton)       Date:  2014-08       Impact factor: 2.506

3.  Evaluation of vancomycin dosing protocols to achieve therapeutic serum concentrations in patients receiving high-flux haemodialysis.

Authors:  Shang-Yi Lin; Mei-Chiou Shen; Shang-Jyh Hwang; Yen-Hsu Chen; Tun-Chieh Chen; Yee-Wen Chiu; Po-Liang Lu
Journal:  Int J Antimicrob Agents       Date:  2014-01-27       Impact factor: 5.283

4.  Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis.

Authors:  Stefaan J Vandecasteele; Dirk De Bacquer; An Sabine De Vriese
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

5.  Vancomycin mass transfer characteristics of high-flux cellulosic dialysers.

Authors:  M K Scott; B A Mueller; W R Clark
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

6.  Pharmacokinetics of vancomycin when administered during high flux hemodialysis.

Authors:  E F Foote; W B Dreitlein; C A Steward; T Kapoian; J A Walker; R A Sherman
Journal:  Clin Nephrol       Date:  1998-07       Impact factor: 0.975

7.  Once-weekly vancomycin for patients receiving high-flux hemodialysis.

Authors:  Brooke S Crawford; Rebecca F Largen; Ted Walton; John J Doran
Journal:  Am J Health Syst Pharm       Date:  2008-07-01       Impact factor: 2.637

8.  Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.

Authors:  L S Welage; N A Mason; E J Hoffman; R M Odeh; J Dombrouski; J A Patel; R D Swartz
Journal:  J Am Soc Nephrol       Date:  1995-10       Impact factor: 10.121

Review 9.  Key considerations in the treatment of complicated staphylococcal infections.

Authors:  R N Jones
Journal:  Clin Microbiol Infect       Date:  2008-03       Impact factor: 8.067

10.  CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.

Authors:  Aroonrut Lucksiri; Meri K Scott; Bruce A Mueller; Richard J Hamburger; Kevin M Sowinski
Journal:  Nephrol Dial Transplant       Date:  2002-09       Impact factor: 5.992

View more
  3 in total

1.  Validation of a Weight Threshold-Based Vancomycin Dosing Protocol for Patients Undergoing Intermittent Hemodialysis.

Authors:  Lu Xuan Lisa Sun; Kang-Wei David Liu; Stephanie Lynch; Mielen Mistry; Heather Wise; Eduard Iliescu
Journal:  Can J Hosp Pharm       Date:  2019-10-21

2.  Treatment of recurrent urinary tract infections in anuric hemodialysis patient, do we really need antimicrobial urinary concentration?

Authors:  Wasim S El Nekidy; Derrick Soong; Mohamad Mooty; Islam M Ghazi
Journal:  IDCases       Date:  2020-03-21

3.  Salvage of Hemodialysis Catheter in Staphylococcal Bacteremia: Case Series, Revisiting the Literature, and the Role of the Pharmacist.

Authors:  Wasim S El Nekidy; Derrick Soong; Albert Kadri; Osama Tabbara; Amina Ibrahim; Islam M Ghazi
Journal:  Case Rep Nephrol Dial       Date:  2018-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.